Life Sciences Notes | Herbert Smith Freehills Kramer | Global law firm

All blog posts

Search all blogs

04 setembro 2024

CJEU finds EC's recent policy of referrals for deals below the merger thresholds illegal - more certainty for companies doing deals?

H1 2024 – a steady start for biopharma M&A

A new Labour Government – what might this mean for the UK life sciences industry?

The EU AI Act Is In Force From Today (1 August 2024)

Commission investigation into anticompetitive disparagement ends with commitments

UPC finds Edwards' patent valid (as amended) – Meril's revocations dismissed

UPC revokes Amgen's patent in the first case filed at the UPC

The EU focuses its Industrial Policy on Critical Industries - STEP Regulation solidifies Biotechnology focus

EU FRAND regulation – what next for FRAND litigation in Europe?

AI In Life Sciences – What Changes To The Regulatory And Innovation Landscape Could The UK Elections Bring?

Recent additions to Life Sciences Notes

Biotech in the crosshairs of global politics - the draft US Biosecure Act

Showing 36 out of 93 results

View more

Key contacts

Laura Orlando

Managing Partner, Milan Office, Milan

Alan Montgomery

Partner, Head of Pharmaceuticals Sector, Chair of India Group, London

Chris Parker KC

Partner, Head of Pharmaceuticals Sector, London